EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of regorafenib plus biweekly trifluridine/tipiracil for refractory metastatic colorectal cancer: a multicenter single-arm phase II trial

Xiangling Wang, Zhen Li, Dan Sha, Haipeng Ren, Cuihua Yi, Shuguang Li, Peng Wang, Yunxia Chu, Changlun Li, Guanglian Shan, Jian Wang, Xiaorong Yang iD und 1 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf129 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Xiangling Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China. Hauptthemen laut MEDLINE: Trifluridine, Phenylurea Compounds, Colorectal Neoplasms, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qilu Hospital of Shandong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Both regorafenib and trifluridine/tipiracil (TAS-102) monotherapies have shown significant but limited survival benefits in metastatic colorectal cancer (mCRC) cases who progress after standard treatments. This study aimed to evaluate the efficacy and safety of regorafenib plus biweekly TAS-102 in refractory mCRC.

Methods

In this single-arm multicenter phase II trial (ChiCTR2300071752), eligible patients received regorafenib at 120 mg/day for 21 days in a 4-week cycle or were treated with a dose-escalation strategy (80 mg/day, followed by weekly increase of 40 mg to 120 mg/day). TAS-102 was administered biweekly (30 mg/m2 bid on days 1-5). The primary endpoint was progression-free survival (PFS). The secondary endpoints included safety, response rate (ORR), disease control rate (DCR), and overall survival (OS).

Results

Between March 1, 2022 and December 1, 2023, 28 patients were enrolled. Totally 24 patients had at least one response evaluation. Median PFS and OS were 4.9 months (95% CI, 4.2-5.6) and 15.4 months (95% CI, 11.1-19.7). The ORR was 8.3% and the DCR was 83.3%. Grade 3 or 4 treatment-related adverse events occurred in 21.4% of patients, including hypertension (7.1%), neutropenia (7.1%), thrombocytopenia (3.6%), and hoarseness (3.6%).

Conclusions

Regorafenib plus biweekly TAS-102 showed promising benefits in refractory mCRC cases, and adverse events were generally tolerable and manageable.

Discussion

(ClinicalTrials.gov Identifier: ChiCTR2300071752. IRB Approved: KYLL-202203-026-1.)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrifluridinePhenylurea CompoundsColorectal NeoplasmsPyridinesPyrrolidinesUracilAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedDrug CombinationsThymineAdultAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

refractory colorectal cancerregorafenibtrifluridine/tipiracil

Substanzen

regorafenibTrifluridinePhenylurea CompoundsPyridinesPyrrolidinestrifluridine tipiracil drug combinationDrug CombinationsUracilThymine

Autor:innen und Institutionen

  • Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China.
  • Department of Medical Oncology, Linyi Cancer Hospital, Linyi, People's Republic of China.
  • Department of Minimally Invasive Comprehensive Treatment of Cancer, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250012, People's Republic of China.
  • Department of Medical Oncology, Weifang People's Hospital, Weifang, People's Republic of China.
  • Department of Oncology, Weifang Yidu People's Hospital, Weifang, People's Republic of China.
  • Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, People's Republic of China.

ORCID-Profile: Xiaorong Yang, Jing Hao

Förderung

  • Qilu Hospital of Shandong University

Zitieren

APA

Wang, X., Li, Z., Sha, D., Ren, H., Yi, C., Li, S., Wang, P., Chu, Y., Li, C., Shan, G., Wang, J., Yang, X., & Hao, J. (2025). Efficacy and safety of regorafenib plus biweekly trifluridine/tipiracil for refractory metastatic colorectal cancer: a multicenter single-arm phase II trial. The Oncologist. https://doi.org/10.1093/oncolo/oyaf129

Vancouver

Wang X, Li Z, Sha D, Ren H, Yi C, Li S, et al. Efficacy and safety of regorafenib plus biweekly trifluridine/tipiracil for refractory metastatic colorectal cancer: a multicenter single-arm phase II trial. The Oncologist. 2025. doi:10.1093/oncolo/oyaf129

BibTeX
@article{Wang2025,
  author = {Wang, Xiangling and Li, Zhen and Sha, Dan and Ren, Haipeng and Yi, Cuihua and Li, Shuguang and Wang, Peng and Chu, Yunxia and Li, Changlun and Shan, Guanglian and Wang, Jian and Yang, Xiaorong and Hao, Jing},
  title = {Efficacy and safety of regorafenib plus biweekly trifluridine/tipiracil for refractory metastatic colorectal cancer: a multicenter single-arm phase II trial},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf129}
}
Kostenlos starten →